TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)
B: Retinal blood flow (in total 8x on 2 study days)
C: A combination of CVD mortality non fatal MI and Stoke at a 4 year follow up.
D: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) (Average follow-up 10.1 years); Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer (Average follow-up 10.1 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
B: Prostate Cancer Deaths (Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.); Prostate Cancer Death Rates (Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.)
C: N/A
D: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: total communication score (2 weeks after information was given)
B: N/A
C: Patients' knowledge about clinical trials measured by the questionnaire Quality of Informed Consent (The questionnaire is sent to patients within a week after consenting to the trial.)
D: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)
B: Major fatal and non fatal ischemic cardiovascular events; Cancer any kind except for basal cell skin carcinoma
C: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
D: cognitive improvement or maintenance of cognitive performance (within 3 months of treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: The goal is to determine the effects of the vitamin C and vitamin E on surrogate markers of atherosclerosis following an atherogenic meal in type 2 diabetes (2 months)
B: Major fatal and non fatal ischemic cardiovascular events; Cancer any kind except for basal cell skin carcinoma
C: Frequency of adverse events (baseline, monthly for 1 year, then 15 and 18 months)
D: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Focal Electroretinogram Amplitude and Phase (6 months)
B: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)
C: Prostate cancer (Ongoing); Total cancer (Ongoing); Major cardiovascular events (Ongoing)
D: N/A

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of selenium and vitamin E, either alone or together, in preventing prostate cancer.


Options:
A: Number of Participants With Prostate Cancer (Every six months for 7 to 12 years depending on when the participant was randomized.)
B: Cellular and Humoral Immune Response (12 weeks)
C: Plasma selenoprotein P levels at 0, 4, 8, 12, 16, 20, 24, 32, and 40 weeks (40 weeks)
D: Major fatal and non fatal ischemic cardiovascular events; Cancer any kind except for basal cell skin carcinoma

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis
Brief Summary: The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).


Options:
A: Rebleed, death (At least 3 months after last enrollment)
B: Survival (10 years)
C: Varices (6 years)
D: Survival (10 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)
B: DNA damage from hydroxyurea therapy-variable-diversity-joining (VDJ) recombination events defined as the number of events per microgram of genomic DNA; (Every 3 years); DNA damage from hydroxyurea therapy-percentage of HJB in immature (CD71+) erythrocytes (Every 3 years)
C: urinary albumin excretion rate (12 months)
D: Percentage of successful treatment of each arm (at 9 months of treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)
B: Pain Rating Using Visual Analog Scale at Day 1 and Day 5 (Day 1 and Day 5)
C: The primary endpoint of the study will be the level of fetal hemoglobin after three months (12 weeks)
D: In vitro response of HbAA and HbSS erythroid cells to NRF2 activation by sulforaphane. (3 months); Safety, physiological effects and cellular effects of daily consumption of broccoli sprout homogenate in a cohort of Hb SS/SB0 thalassemia adult SCD patients (1-2 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side (Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).)
B: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)
C: Occurrence of an Adjudicated Secondary Stroke During the 30-month Treatment Period (Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)); Liver Iron Content (LIC) Change-from-baseline (Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months))
D: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct (From study entry to study exit)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: N/A
B: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct (From study entry to study exit)
C: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)
D: Cerebral vasculopathy (1 year)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Acute Chest Syndrome (Chest x-rays (CXR) were ordered for trial eligibility, as a result of clinical indications, or at discharge or 72 hours if no prior CXR.)
B: N/A
C: Occurrence of an Adjudicated Secondary Stroke During the 30-month Treatment Period (Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months)); Liver Iron Content (LIC) Change-from-baseline (Because the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 30 Months))
D: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Distribution of the Density of Hemoglobin SC Red Cells (measured 2 months after initiation of treatment)
B: Number of Malaria Episodes (12 months)
C: Difference in TCD Time-averaged Mean Velocity (TAMV) on the Index Side (Since the study was terminated early, time frame is from beginning of treatment until end of treatment (up to 24 Months).)
D: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)
Brief Summary: The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.


Options:
A: Treatment Differences of the Change in Qualitative Splenic Function From Baseline (Before initiation of treatment and at 2 years)
B: Number of Malaria Episodes (12 months)
C: Incidence rate of clinical stroke or TIA (3 Years)
D: Fetal Hemoglobin (HbF) Response Following Six Months of Hydroxyurea Therapy (6 months after starting daily hydroxyurea therapy)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Inhaled NO for the Prevention of Chronic Lung Disease
Brief Summary: To determine whether or not inhaled nitric oxide (iNO) safely decreases the incidence of chronic lung disease (CLD) in premature infants.


Options:
A: Survival without chronic lung disease (CLD) (36 weeks)
B: Participant's survival without CLD ((measured at 36 weeks after birth))
C: Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality (Week 36 or earlier, if participants are discharged from the hospital); Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality Stratified by Birth Weight (Randomization to discharge)
D: Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress (21 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Activity for Adolescent Girls (TAAG)
Brief Summary: To test the effectiveness of a multicomponent school-based and community-linked intervention in preventing the decline in physical activity levels and cardiovascular fitness in girls in grades 6-8.


Options:
A: Change in BMI z-score (Baseline (0 months) and 9 months)
B: Body mass index (BMI) >= 85th percentile, adjusted for gender and age (baseline, end of 7th grade, end of study); Fasting glucose (mg/dL) (baseline, end of study); Fasting insulin (mU/mL) (baseline, end of study)
C: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-2 year intervention); MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-3 year intervention)
D: Improvement of maximal oxygen uptake

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Activity for Adolescent Girls (TAAG)
Brief Summary: To test the effectiveness of a multicomponent school-based and community-linked intervention in preventing the decline in physical activity levels and cardiovascular fitness in girls in grades 6-8.


Options:
A: Change in body mass index (BMI) (Baseline, Month 3)
B: Changes in the composite ICH score of adolescents from baseline to year 2 and 4 (2 and 4 years)
C: Body mass index (BMI) >= 85th percentile, adjusted for gender and age (baseline, end of 7th grade, end of study); Fasting glucose (mg/dL) (baseline, end of study); Fasting insulin (mU/mL) (baseline, end of study)
D: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-2 year intervention); MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-3 year intervention)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Activity for Adolescent Girls (TAAG)
Brief Summary: To test the effectiveness of a multicomponent school-based and community-linked intervention in preventing the decline in physical activity levels and cardiovascular fitness in girls in grades 6-8.


Options:
A: % Body Fat (Boys) (Baseline and 3 years); BMI Z-score (Boys) (Baseline and three years); % Body Fat (Girls) (Baseline and 3 years); BMI Z-score (Girls) (Baseline and three years)
B: HIV-1 seroincidence; HSV2 seroprevalence
C: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-2 year intervention); MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-3 year intervention)
D: Daily physical activity > 60 minutes (4 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Activity for Adolescent Girls (TAAG)
Brief Summary: To test the effectiveness of a multicomponent school-based and community-linked intervention in preventing the decline in physical activity levels and cardiovascular fitness in girls in grades 6-8.


Options:
A: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-2 year intervention); MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-3 year intervention)
B: standardized body mass index (zbmi)
C: To evaluate and compare in overweight children the effectiveness of the following interventions: a parent-centered dietary modification program; a physical activity skill development program; and a parent-centered dietary modification + physical activity skill development program.
D: N/A

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Activity for Adolescent Girls (TAAG)
Brief Summary: To test the effectiveness of a multicomponent school-based and community-linked intervention in preventing the decline in physical activity levels and cardiovascular fitness in girls in grades 6-8.


Options:
A: % Body Fat (Boys) (Baseline and 3 years); BMI Z-score (Boys) (Baseline and three years); % Body Fat (Girls) (Baseline and 3 years); BMI Z-score (Girls) (Baseline and three years)
B: Smoking prevalence of adolescents in each group (six years)
C: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-2 year intervention); MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) (Post-3 year intervention)
D: Change in body mass index (Baseline, 1-year post-intervention)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for liver metastases.

PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have liver metastases from colorectal cancer.


Options:
A: Operative blood loss (From skin incision to completion of operation); Operative time (From skin incision to completion of operation)
B: To determine if ANH reduces the requirement for allogeneic red cell transfusions in patients undergoing major hepatic resection or pancreaticoduodenectomy compared to standard intraoperative management (All patients will have their blood checked every 30 minutes during surgery)
C: N/A
D: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels (L-FABP area under curve from start of surgery up until postoperative day 3)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder
Brief Summary: This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a 6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced medication management intervention will accompany all treatment conditions. Follow-up assessments will be completed at 9 and 12 months after treatment.


Options:
A: Severity of Alcohol Use (ASI Alcohol Composite Scores) (Administered at baseline and 3 months, 6 months and 12 months post baseline.); ASI Drug Composite Score (1 year)
B: Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV) (Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)); Drinking Timeline Follow-back Interview (TFBI) (Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up))
C: Decrease from baseline in PTSD symptom severity (Clinician Administered PTSD Scale (CAPS) score (30 day)) at 3-months and at 6-months (Baseline, 3-month, & 6-month follow-ups); Decrease from baseline in positive toxicology screens (urine drug screen and breathalyzer) at 3-months and at 6-months (Baseline, 3-month, & 6-month follow-ups); Decrease from baseline in drug and alcohol symptom severity (Addiction Severity Index (ASI)-Self Administered (30 day)) at 3-months and at 6-months (Baseline, 3-month, & 6-month follow-ups); Decrease from baseline in frequency of substance use (Timeline Follow-Back (TLFB) Interview (90 day)) at 3-months and at 6-months (Baseline, 3-month, & 6-month follow-ups)
D: Alcohol and drug use (3, 6, and 12 months after baseline); Alcohol and drug-related problems (3, 6, and 12 months after baseline); Nights Hospitalized (3, 6, and 12 months after baseline and up to 2 years after the last subject is enrolled); Emergency department visits (3, 6, and 12 months after baseline and up to 2 years after the last subject is enrolled)

Answer: B